drugset
drugset / Trial / NCT05902988

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

NCT05902988 ↗

Phase 1/2 Recruiting 200 enrolled Volastra Therapeutics, Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.

Timeline

Start
2023-10-18
Primary completion
2026-06
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject VLS-1488 Unknown — Oral

Indications

endometrium neoplasm head and neck squamous cell carcinoma non-small cell squamous lung carcinoma ovarian carcinosarcoma ovarian serous adenocarcinoma triple-negative breast carcinoma uterine carcinosarcoma